Novo Nordisk’s weight loss drug Wegovy is set to hit the French market on Tuesday, offering a new option for those looking to shed extra pounds. The medication, which will require a prescription, contains the same active ingredient as the diabetes drug Ozempic, which has gained popularity among celebrities for its weight loss benefits.
While Wegovy is not covered by social security in France, it provides a promising solution for individuals struggling with obesity. The drug works by targeting the appetite control system in the brain, helping to reduce food intake and promote weight loss.
The availability of Wegovy in France represents a significant step forward in the fight against obesity, a growing public health concern. With obesity rates on the rise globally, innovative medications such as Wegovy offer a much-needed tool for individuals looking to improve their health and well-being.
As Novo Nordisk’s weight loss drug becomes available in French pharmacies, it will be interesting to see how it is received by healthcare professionals and patients alike. With its unique mechanism of action and potential for significant weight loss, Wegovy has the potential to make a positive impact on the lives of those struggling with obesity.
Overall, the introduction of Wegovy in France reflects the continued efforts to address the obesity epidemic and provide effective solutions for individuals looking to achieve a healthier weight.
Watch the video by FRANCE 24 English
Video “Novo Nordisk’s weight loss drug Wegovy available in France from Tuesday • FRANCE 24 English” was uploaded on 10/08/2024 to Youtube Channel FRANCE 24 English